A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)
Primary Objective
To evaluate whether the combination of semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor (CILO) and firsocostat (FIR) (hereafter referred to as CILO/FIR) causes fibrosis improvement and NASH resolution in subjects with compensated cirrhosis due to NASH
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
University of Colorado Hospital
Principal Investigator
Amanda Wieland, MD
Study ID
Protocol Number: 21-4639
More information available at ClinicalTrials.gov: NCT04971785
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers